Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice

Hepatology Research

Volumn 44, Issue 8, 2014, Pages 888-896

  Kishina, Manabu ^a   Koda, Masahiko ^a   Kato, Jun ^a   Tokunaga, Shiho ^a   Matono, Tomomitsu ^a   Sugihara, Takaaki ^a   Ueki, Masaru ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Direct renin inhibitors; Liver fibrosis; Liver steatosis; Non alcoholic steatohepatitis; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ALISKIREN; ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KUPFFER CELL; LIVER FIBROSIS; LIVER WEIGHT; MALE; METABOLIC SYNDROME X; MOUSE; NICK END LABELING; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; THERAPY EFFECT;

EID: 84904738043     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12186     Document Type: Article

References (26)

1. Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 2010; 19: 415-423.
2. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 (Suppl 1): 63-69.
3. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008; 14: 185-192.
4. Marique C, Lastra G, Gardner M, Sowers JR. The rennin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 2009; 93: 569-582.
5. De Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010; 100: 525-534.
6. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002; 123: 1667-1676.
7. Ueki M, Koda M, Yamamoto S, Matsunaga Y, Murawaki Y. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 2006; 41: 996-1004.
8. Kato J, Koda M, Kishina M etal. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Int J Mol Med 2012; 30: 107-113.
9. Ueki M, Koda M, Shimizu T, Mitsuda A, Yamamoto T, Murawaki Y. Effect of an angiotensin- II type 1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C : a prospective study. Hepatogastroenterology 2009; 56: 1100-1104.
10. El-Demerdash E, Salam OMA, El-Batran SA, Abdallah HM, Shaffie NM. Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats. Clin Exp Pharmacol Physiol 2008; 35: 159-167.
11. Ueki M, Koda M, Matono T, Sugihara T, Maeda K, Murawaki Y. Preventative and therapeutic effects of perindopril on hepatic fibrosis induced by bile duct ligation in rats. Mol Med Rep 2009; 2: 857-864.
12. Hirose A, Ono M, Saibara T etal. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45: 1375-1381.
13. Kurita S, Takamura T, Ota T etal. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. Eur J Pharmacol 2008; 588: 316-324.
14. Wu WP, Chang CH, Chiu YT etal. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol 2010; 299: 929-941.
15. Soga M, Kishimoto Y, Kawaguchi J etal. The FLS mouse: a new inbred strain with spontaneous fatty liver. Lab Anim Sci 1999; 49: 269-275.
16. ob gene. Exp Anim 2010; 59: 407-419.
17. Sugihara T, Koda M, Kishina M etal. Fatty liver Shionogi-ob/ob mouse: a new candidate for a non-alcoholic steatohepatitis model. Hepatol Res 2013; 43: 547-556.
18. Wouters K, Gorp PJV, Bieghs V etal. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48: 474-486.
19. Rooyen DMV, Larter CZ, Haigh WG etal. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-1403.
20. Aihara Y, Yoshiji H, Noguchi R etal. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol Res 2013; [Epub ahead of print].
21. Lee KC, Chan CC, Yang YY, Hsieh YC, Huang YH, Lin HC. Aliskiren attenuates chronic carbon tetrachloride-induced liver injury in mice. Eur J Clin Invest 2012; 42: 1261-1271.
22. Luo X, Yang Y, Shen T etal. Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells. Nutr Metab (Lond) 2012; 9: 34.
23. Obstfeld AE, Sugaru E, Thearle M etal. C-C chemokine receptor 2(CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 2010; 59: 916-925.
24. Kanda H, Tateya S, Tamori Y etal. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.
25. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008; 57: 3297-3306.
26. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev 2012; 13: 136-149.